EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Twist Bioscience's enterprise value is $1,577.7 Mil.
Twist Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $262.4 Mil. Therefore, Twist Bioscience's EV-to-Revenue for today is 6.01.
The historical rank and industry rank for Twist Bioscience's EV-to-Revenue or its related term are showing as below:
TWST'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.68 Med: 13.42 Max: 81.27
Current: 6.01
During the past 8 years, the highest EV-to-Revenue of Twist Bioscience was 81.27. The lowest was 1.68. And the median was 13.42.
TWST's EV-to-Revenue is ranked worse than 71.24% of 226
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.07
vs TWST: 6.01
As of today (2024-04-26), Twist Bioscience's stock price is $31.54.
Twist Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.59. Therefore, Twist Bioscience's PS Ratio for today is 6.87.
Twist Bioscience EV-to-Revenue Historical Data
The historical data trend for Twist Bioscience's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Twist Bioscience's EV-to-Revenue
For the Diagnostics & Research subindustry, Twist Bioscience's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's EV-to-Revenue falls into.
Twist Bioscience's current Enterprise Value is $1,577.7 Mil.
Twist Bioscience's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $262.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience's share price for today is $31.54.
Twist Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Twist Bioscience's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Twist Bioscience (Twist Bioscience) Business Description
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TWST has been successfully added to your 